Florbetaben

Summary

Florbetaben (CHEMBL1908906) is an approved small molecule; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 10
• Chemistry: 359.4 Da · C21H26FNO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908906
Name	Florbetaben
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	53257383
Molecular formula	C21H26FNO3
Molecular weight	359.4
InChIKey	NCWZOASIUQVOFA-NSCUHMNNSA-N

SMILES: CNC1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)OCCOCCOCCF

IUPAC name: 4-[(E)-2-[4-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline

Also known as: Florbetaben, Florbetaben unlabelled, FLORBETABEN

Parent form; salt/anhydrous children: CHEMBL566752

Patent coverage: 133 distinct patent families (305 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
Not specified	4
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01020838	PHASE3	COMPLETED	Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
NCT00750282	PHASE2	COMPLETED	Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer’s Disease Compared to Healthy Volunteers
NCT00928304	PHASE2	COMPLETED	Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
NCT03744312	PHASE1/PHASE2	COMPLETED	Imaging Inflammation in Alzheimer’s Disease With 11C-ER176
NCT01138111	PHASE1	COMPLETED	Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
NCT04105634	EARLY_PHASE1	TERMINATED	Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT
NCT03507257	Not specified	RECRUITING	Longitudinal Early-onset Alzheimer’s Disease Study Protocol
NCT01297114	Not specified	COMPLETED	Imaging of Cognition, Learning, and Memory in Aging
NCT02362880	Not specified	TERMINATED	Study of Genetic Alzheimer’s Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study
NCT04510168	Not specified	COMPLETED	Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).